期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

含服阿仑膦酸钠致创伤性溃疡三例并文献复习 被引量：1

Three cases of oral traumatic ulcers induced by keeping alendronate sodium in the mouth and review of literature
原文传递
导出
摘要 骨质疏松（osteoporosis）是一种以骨量降低和骨组织微结构破坏为特征，导致骨脆性增加和易于骨折的代谢性骨病；临床表现以弥漫性骨痛、骨折为主[1,2]。阿仑膦酸钠能明显缓解骨质疏松性骨痛，显著提高骨密度，增加骨强度，
作者 段丽君 江霞 李峥
机构地区 天津市第一中心医院内分泌科 天津市第一中心医院口腔科
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2011年第10期862-863,共2页 Chinese Journal of Endocrinology and Metabolism
关键词 阿仑膦酸钠 创伤性溃疡 文献复习 骨质疏松性骨痛 含服 代谢性骨病 临床表现 骨组织
分类号 R595.3 [医药卫生—内科学]
  • 相关文献

参考文献17

  • 1American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis:2001update.Arthritis Rheum,2001,44:1496-1503.
  • 2廖二元.骨质疏松症.见:陆再英,钟南山,主编.内科学.第7版.北京:人民卫生出版社,2008,835-840.
  • 3季秉琦.口腔粘膜学.第2版.北京:人民卫生出版社,2005,61-62.
  • 4Cummings SR,Black DM,Thompson DE,et al.Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures:results from the Fracture Intervention Trial.JAMA,1998,280:2077-2082.
  • 5Bone HG,Hosking D,Devogelaer JP,et al.Ten years' experience with alendronate for osteoporosis in postmenopaussl women.N Engl J Med,2004,350:1189-1199.
  • 6陈亚萍,周红霞,石国勋.阿仑膦酸钠治疗老年人骨质疏松的临床观察[J].中华老年医学杂志,2008,27(11):835-836. 被引量：2
  • 7王巧宏,吴华香,黄永禄,薛静,杨旭燕,朱亮,温丽虹.应用阿仑膦酸钠预防免疫性疾病糖皮质激素性骨质疏松症[J].中华医学杂志,2008,88(27):1888-1891. 被引量：3
  • 8de Groen PC,Lubbe DF,Hirsch LJ,et al.Esophagitis associated with the use of alendronate.N Engl J Med,1996,335:1016-1021.
  • 9Donahue JG,Chant KA,Andrade SE,et al.Gastric and duodenal safety of daily alendronate.Arch Intern Med,2002,162:936-942.
  • 10G6mez V,Xiao SY.Alendronate-induced esophagitis in an elderly woman.Int J Clin Exp Pathol,2009,2:200-203.

二级参考文献15

  • 1American College of Rheumatology Ad Hoc Committee on Glucocoritoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis; 2001 update. Arthritis Rheum, 2001, 44: 1496-1503.
  • 2Saag KG. Prevention of glucocorticoid-induced osteoporosis. South Med J, 2004, 97:555-558.
  • 3Devogelaer JP, Goemaere S, Boonen S, et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int, 2006, 17:8-19.
  • 4Boling EP. Secondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosis. Clin Ther, 2004, 26: 1-14.
  • 5Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med, 1998, 339:292-299.
  • 6Levis S, Ahman R. Bone densitometry: clinical considerations. Arthritis Rheum, 1998,41:577-587.
  • 7Michael B. Effective pharmacotherapeutic interventions for the prevention of hip fractures. Endocrinologist, 2002, 12: 29-37.
  • 8Hirayama T, Sabokbar A, Athanasou NA. Effect of corticosteroids on human osteoclast fomation and activity. J Endocrinol, 2002, 175:155-163.
  • 9Rodan GA. Fleisch HA. Bisphosphonates:mechanisms of action. J Clin Invest, 1996,97:2692-2696.
  • 10Compston J. Glucocorticoid-induced osteoporosis. Horm Res, 2003, 60 Suppl 3:77-79.

共引文献3

同被引文献30

引证文献1

二级引证文献6

中华内分泌代谢杂志
2011年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部